IEFM
TEVA icon

IQ EQ Fund Management’s Teva Pharmaceuticals TEVA Stock Holding History

IQ EQ Fund Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-93,084
Closed -$949K – 310
2023
Q3 		$949K Sell
93,084
-28,938
-24% -$269K 0.2% 140
2023
Q2 		$919K Hold
122,022
– – 0.17% 128
2023
Q1 		$1.08M Sell
122,022
-18,587
-13% -$184K 0.21% 122
2022
Q4 		$1.28M Buy
140,609
+6,992
+5% +$61K 0.26% 113
2022
Q3 		$1.08M Buy
+133,617
New +$1.18M 0.24% 121
2022
Q1 		– Sell
-141,219
Closed -$1.13M – 227
2021
Q4 		$1.13M Buy
141,219
+12,889
+10% +$116K 0.17% 146
2021
Q3 		$1.25M Sell
128,330
-38,618
-23% -$362K 0.19% 138
2021
Q2 		$1.65M Buy
166,948
+41,804
+33% +$442K 0.25% 125
2021
Q1 		$1.44M Buy
125,144
+107,843
+623% +$1.24M 0.25% 138
2020
Q4 		$167K Buy
+17,301
New +$166K 0.04% 224

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

IQ EQ Fund Management's TEVA Position: Q4 2023 in Review

IQ EQ Fund Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 93,084 shares — an estimated $949K sold.

IQ EQ Fund Management first reported a position in TEVA in Q4 2020 and held it in 10 quarters. The position peaked at $1.65M in Q2 2021. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • IQ EQ Fund Management reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • IQ EQ Fund Management sold 93,084 Teva Pharmaceuticals shares in Q4 2023, an estimated $949K.
  • IQ EQ Fund Management first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • IQ EQ Fund Management's Teva Pharmaceuticals position peaked at $1.65M in Q2 2021.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on IQ EQ Fund Management's 13F filing for Q4 2023, filed 9 Feb 2024.